What Is a Randomized Controlled Trial? RCTs Explained

TL;DR: A randomized controlled trial (RCT) is a study in which participants are randomly assigned to an active intervention group or a control group, allowing researchers to attribute differences in outcomes to the intervention rather than pre-existing group differences. RCTs sit at the top of the single-study evidence hierarchy because randomization is the most powerful tool available for controlling confounding in human research. Most research peptides, including BPC-157, TB-500, and semaglutide before its RCT program, lack this level of human evidence. Understanding what an RCT is, and how to assess its quality, is a foundational skill for anyone reading peptide research critically.

Research-Use Disclaimer: This article is for educational and research reference purposes only. The compounds referenced are cited as scientific examples. This content does not constitute medical advice, does not recommend human administration of any compound, and does not describe protocols for personal use. For adults 21+ with a research interest only.

What Is a Randomized Controlled Trial?

A randomized controlled trial is a prospective experimental study design in which human participants are randomly allocated to one of two or more groups: an intervention group receiving the compound or procedure under investigation, and a control group receiving either a placebo, a comparator treatment, or standard care. The defining feature is randomization, the use of a chance-based mechanism to determine group assignment, rather than researcher judgment, participant preference, or any other non-random process.

Because group assignment is determined by chance, randomization distributes both measured and unmeasured confounding variables approximately equally between the groups at the start of the trial. This is the critical design advantage of the RCT: it means that at the end of the trial, a statistically significant difference in outcomes between groups is most plausibly explained by the intervention itself, rather than by pre-existing differences between participants. No other study design routinely achieves this.

RCTs are used to establish whether a compound, intervention, or procedure has a causal effect on a defined outcome in a living human population. For any compound claiming evidence of efficacy in humans, whether an approved pharmaceutical or a research peptide, the question a researcher should always ask is: has this been evaluated in an RCT?

For the applied researcher reading peptide literature, understanding RCT anatomy is practical: it allows evaluation of which evidence claims are human-validated vs. animal-only, and which trial design features strengthen or weaken a finding.

The Key Components of an RCT

1. Randomization

Randomization is the act of assigning participants to groups using a random mechanism, typically a computer-generated random number sequence, rather than any systematic or discretionary method. Properly executed randomization prevents selection bias, the systematic difference between groups that would arise if researchers or participants could influence group assignment.

There are several randomization methods used in published trials:

• Simple randomization: Each participant is assigned with equal probability to any group, similar to a coin flip. Works well for large trials; in small trials, it can produce unequal group sizes by chance.
• Block randomization: Participants are randomized in fixed-size blocks to ensure balanced group sizes at any point in the trial. Commonly used in small-to-medium trials.
• Stratified randomization: Participants are first grouped by a key characteristic (e.g., age, disease severity, sex), and randomization is performed within each stratum. This ensures that potential confounders are distributed equally between groups even in smaller samples.
• Minimization: An adaptive method that dynamically assigns participants to the group that will minimize imbalance on multiple prognostic factors simultaneously.

The STEP 1 trial of semaglutide, published in the New England Journal of Medicine by Wilding et al. (2021) and indexed on PubMed as PMID 33567185, illustrates stratified block randomization in a large Phase III context: 1, 961 participants without diabetes were randomly assigned 2:1 to subcutaneous semaglutide 2.4 mg or placebo for 68 weeks, with randomization stratified by region and glycated hemoglobin level. The trial found a mean body weight reduction of 14.9% in the semaglutide group vs. 2.4% with placebo (estimated treatment difference: −12.4 percentage points; 95% CI, −13.4 to −11.5; P<0.001). This is what RCT-level evidence looks like: a precise effect estimate with confidence intervals, a p-value, and a design that controls for known confounders through stratification.

2. Control and Placebo Groups

A control group is the comparator against which the intervention group is evaluated. The most common form of control in drug trials is the placebo: an inert substance, identical in appearance, taste, and delivery route to the active compound, that allows the trial to separate the pharmacological effect of the compound from the placebo effect, where participants improve simply because they believe they are receiving a treatment.

Not all trials use a placebo control. When an existing standard of care exists, it may be unethical to withhold it, in which case the control is the active standard treatment rather than an inert placebo. This is called an active-controlled or comparator trial. The SURPASS-2 trial comparing tirzepatide to semaglutide, published in the New England Journal of Medicine by Frías et al. (2021), PMID 34170647, used this design: 1, 879 participants with type 2 diabetes were randomized to tirzepatide (5 mg, 10 mg, or 15 mg) or semaglutide 1 mg, with the primary endpoint being change in glycated hemoglobin (HbA1c) at 40 weeks. An active comparator RCT can only demonstrate whether one compound outperforms another, not whether either compound works vs. no treatment at all, a distinction that matters when interpreting results.

The choice of control group should be clearly stated in a published trial’s methods section, and a researcher evaluating any RCT should identify what the control was before interpreting the effect size.

3. Blinding: Single, Double, and Triple

Blinding (also called masking) refers to keeping participants, researchers, or outcome assessors unaware of which group each participant has been assigned to. Blinding addresses performance bias and detection bias, two systematic errors that can inflate or distort observed effects.

The STEP 1 and STEP 2 semaglutide trials were double-blind and placebo-controlled, with participants and investigators masked to group assignment, a design feature that strengthens confidence in the observed weight-reduction effect. The SURPASS-2 trial comparing tirzepatide to semaglutide was open-label, which is a design limitation to note when interpreting that trial’s secondary outcomes, even though the primary endpoint (HbA1c change, an objective laboratory measure) is less susceptible to detection bias than subjective outcomes.

When reading any trial, the methods section should explicitly state what blinding was applied and to whom. A claim that a compound “showed efficacy in a clinical trial” that turns out to be an open-label single-arm study carries far less weight than a double-blind RCT.

4. Allocation Concealment

Allocation concealment is a distinct concept from blinding that is often confused with it, and it is equally important. Allocation concealment refers to the process that prevents investigators from knowing which treatment a participant will receive before the participant is enrolled and assigned, thereby preventing investigators from consciously or unconsciously assigning healthier or sicker participants to a preferred group.

Common methods include centralized telephone or web-based randomization systems (as used in the STEP 2 trial, which used an interactive web-response system), sequentially numbered sealed opaque envelopes, or pharmacy-controlled dispensing. Poor allocation concealment is associated with inflated effect estimates in published trials: a 2001 meta-epidemiological analysis by Schulz and Grimes in The Lancet documented that trials with inadequate concealment systematically overestimate treatment effects compared to trials with adequate concealment.

When evaluating a trial, look for the phrase “allocation concealment” or its equivalent in the methods section. If a paper does not describe how concealment was achieved, this is a reporting gap, and potentially a quality gap, worth flagging.

5. Intention-to-Treat Analysis

The intention-to-treat (ITT) principle specifies that participants should be analyzed in the group to which they were originally randomized, regardless of whether they actually completed the trial, adhered to the protocol, or received the assigned treatment. This is in contrast to per-protocol analysis, which only includes participants who completed the study as planned.

ITT analysis is the standard for the primary analysis in most well-designed RCTs because it preserves the benefits of randomization. If the analysis only includes completers (per-protocol), it reintroduces selection bias: the participants who drop out may systematically differ from those who complete the trial in ways that affect outcomes, effectively breaking the randomization. For example, participants who experience side effects may be more likely to drop out of an active-treatment group, and excluding them from the analysis would overestimate the tolerability and efficacy of the compound.

The STEP 1 trial reported both an ITT analysis (the primary analysis) and a per-protocol analysis as a sensitivity analysis. This is best practice: the ITT result answers the policy question (“what happens in a real-world population, including those who discontinue?”), while the per-protocol result answers the biological question (“what happens in participants who take the drug as prescribed?”). Researchers comparing trial results across compounds should always confirm whether effect sizes reported come from ITT or per-protocol analyses, as the latter typically show larger effects.

Why RCTs Sit High in the Evidence Hierarchy

The evidence hierarchy in biomedical research ranks study designs by their capacity to establish causal relationships and control bias. Systematic reviews and meta-analyses of multiple well-conducted RCTs sit at the apex, followed by individual RCTs, cohort and observational studies, animal model studies, in vitro experiments, and mechanistic or theoretical models. For a detailed explanation of each tier and the Legendary Labz 4-tier framework applied to peptide research compounds, see How to Read an Evidence Tier in Peptide Research.

The RCT’s position in the hierarchy is not arbitrary. It reflects a specific logical property: randomization is the only method available in prospective human research that systematically controls for both known and unknown confounders simultaneously. Observational studies can adjust statistically for measured confounders, but residual confounding from unmeasured variables remains a persistent threat. Animal studies face the additional problem of cross-species translational uncertainty. In vitro experiments cannot replicate the complexity of in vivo pharmacokinetics or whole-organism physiology.

For the peptide researcher, this means the following claim is always logically available: even if the animal data on compound X is extensive and internally consistent, the question of whether that effect occurs in humans has not yet been answered by any study in the RCT evidence tier. That is a fact about the state of the evidence, not a criticism of the animal research, and stating it accurately is what research literacy looks like in practice.

To understand how to evaluate the tiers below RCT level, including how to read animal model data critically, see Animal Model Research Explained and How to Read a PubMed Abstract.

RCTs in Peptide Research: Why Many Compounds Lack Them

The peptide research landscape is characterized by a significant gap: a substantial body of preclinical literature exists for many compounds, but few have been evaluated in Phase III human RCTs for the indications most commonly studied in research settings. Understanding why this gap exists, rather than simply noting it, is useful context for any researcher.

To conduct an authorized human trial in the United States, a researcher or sponsor must first file an Investigational New Drug (IND) application with the FDA and receive clearance. This requires preclinical safety data (toxicology, pharmacokinetics, initial dose-range studies), manufacturing quality documentation, and an approved clinical protocol. Phase I trials then assess safety and tolerability in healthy volunteers. Only after Phase I do compounds proceed to Phase II (preliminary efficacy) and Phase III (pivotal efficacy against placebo or active comparator). The entire pipeline from IND to Phase III completion typically takes 8–12 years and costs tens to hundreds of millions of dollars.

For compounds like semaglutide and tirzepatide, which entered human trials as proprietary pharmaceutical assets backed by major pharmaceutical programs, this investment was made, and the compounds now have extensive Phase III RCT data. For compounds like semaglutide, the STEP trial program alone enrolled more than 4, 500 participants across multiple Phase III trials.

By contrast, most peptide compounds studied in preclinical contexts, including BPC-157, TB-500, Ipamorelin, Epithalon, and many others, have not been taken through the IND process by any sponsor for the indications studied in animal models. This is not because the animal data is weak; in several cases (BPC-157 being the clearest example) the preclinical evidence base is genuinely extensive. It reflects the economic reality that Phase III trials require a commercial sponsor with the resources and regulatory pathway to proceed. Without this infrastructure, compounds remain at the preclinical tier regardless of how many animal studies have been published.

This is the honest state of the evidence for most research peptides as of 2026. It does not mean that animal data should be dismissed, it provides biologically plausible signals that justify further investigation. But it means that a claim of “shown to work in humans” cannot be made for these compounds on the basis of animal studies alone. For more on how to evaluate what compound X’s research actually shows, see P-Values and Effect Sizes Explained.

The regulatory status of compounds classified as research peptides is covered in detail in the guide. For the FDA status of research peptides specifically, see FDA Status of Research Peptides Explained.

How to Spot RCT Quality: The CONSORT Statement

Not all RCTs are equally well conducted or reported. The quality of an RCT depends on how well its design features, randomization, blinding, allocation concealment, ITT analysis, were actually implemented and whether the reporting is transparent enough for a reader to evaluate those features. Poor reporting hides poor methodology; rigorous reporting reveals it.

The standard tool for evaluating and reporting RCT quality is the CONSORT statement (Consolidated Standards of Reporting Trials). According to PubMed-retrieved data, the CONSORT 2010 Statement, published by Schulz KF, Altman DG, and Moher D in the BMJ (2010), provides a 25-item checklist and flow diagram specifying what information a properly reported RCT must disclose, including how randomization was generated, how allocation concealment was implemented, who was blinded and how, how missing data were handled, and what pre-specified primary outcomes were analyzed (DOI: 10.1136/bmj.c332, PMID 20332509). The CONSORT statement is adopted by hundreds of journals as a condition of publication and is the international standard for RCT transparency.

What CONSORT asks for, and why it matters: The CONSORT checklist requires trial authors to report exactly how participants were randomized (including the specific method), whether allocation was concealed and how, which participants were blinded and by what mechanism, the numbers enrolled and analyzed in each group (via a flow diagram), and all pre-specified outcomes, not just those that showed favorable results. This last requirement is critical for detecting selective outcome reporting, where only statistically significant endpoints from a trial are published while null results are omitted.

When reading any published trial, including any future human trial of a peptide compound, a researcher can use the CONSORT framework as a structured checklist:

• Randomization: Is the method described? (e.g., “computer-generated random number sequence” vs. vague “randomly assigned”)
• Allocation concealment: How was concealment achieved before enrollment? (central web system, sealed envelopes, pharmacy control?)
• Blinding: Who was blinded? Participants? Investigators? Outcome assessors? Was blinding successfully maintained?
• Primary outcome: Was the primary endpoint pre-specified before data collection? Is there a registry entry (ClinicalTrials.gov) that confirms this?
• ITT analysis: Were all randomized participants included in the primary analysis?
• CONSORT flow diagram: Does the paper include a figure showing how many participants were screened, enrolled, randomized, completed, and analyzed? Any paper missing this is not CONSORT-compliant.

A trial that reports all CONSORT items transparently allows a reader to independently assess the study’s internal validity. A trial with vague or missing reporting of these items should be interpreted with caution, the missing detail may indicate that the trial was poorly conducted, or that unfavorable aspects of the methodology are being obscured.

The CONSORT statement has been extended to multiple special trial designs. For non-inferiority and equivalence trials, such as SURPASS-2, which tested whether tirzepatide was non-inferior to semaglutide, a separate CONSORT extension exists (Piaggio et al., JAMA 2012, PMID 23268518, DOI: 10.1001/jama.2012.87802). Understanding the applicable CONSORT extension helps a researcher assess whether the right statistical framework was applied for the research question being asked.

Frequently Asked Questions About Randomized Controlled Trials

What is a randomized controlled trial (RCT)?

A randomized controlled trial is a study design in which participants are randomly assigned to either an active intervention group or a control group (typically receiving a placebo or standard care). Random assignment distributes known and unknown confounding variables approximately equally between groups, allowing researchers to attribute observed differences in outcomes to the intervention rather than to pre-existing differences between participants. RCTs are the primary design for establishing causal evidence of a treatment effect in living humans.

Why do RCTs sit at the top of the evidence hierarchy?

RCTs produce the strongest causal evidence for a treatment effect in humans because randomization controls for confounding, the primary threat to valid causal inference in non-experimental research. When participants are randomized, both measured and unmeasured confounders are distributed approximately equally between groups, so end-of-trial differences are most plausibly explained by the intervention. Systematic reviews and meta-analyses of multiple well-conducted RCTs sit above individual RCTs in the hierarchy, but the RCT is the foundational unit of human causal evidence. Learn more about the full hierarchy in How to Read an Evidence Tier in Peptide Research.

What is double-blind design in an RCT and why does it matter?

In a double-blind RCT, neither the participants nor the researchers assessing outcomes know which group each participant is in. This prevents performance bias, where participants behave differently because they know whether they are receiving the active treatment, and detection bias, where investigators unconsciously rate outcomes differently based on group assignment. Double-blinding is considered standard for trials measuring subjective outcomes such as pain, fatigue, or self-reported wellbeing. Trials measuring objective endpoints (e.g., HbA1c via laboratory assay, or weight on a calibrated scale) are less susceptible to detection bias, which is why open-label designs are sometimes used for objective primary endpoints while remaining a limitation for subjective secondaries.

Why do most research peptides lack RCT evidence?

Conducting a Phase III RCT requires first clearing the FDA’s Investigational New Drug (IND) process, completing Phase I safety trials, and then running multi-year Phase II and Phase III efficacy trials. This process typically requires 8–12 years and tens to hundreds of millions of dollars. Most research peptides have not been taken through this pipeline by any commercial sponsor for the indications studied in animal models. Their evidence bases consist primarily of preclinical data, which is scientifically informative but cannot substitute for human RCT evidence in establishing efficacy or safety in humans.

For educational and research reference purposes only. Not medical advice. Not for human use.